CANF Stock Posts

CANF Can Fite Biofarma6.57+0.04+0.6%

Premarket:5.90-0.67 (-10.2%)

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

Business WireWed, 11-Jan 9:04 AM

CANF Can Fite Biofarma1.27+0.14+12.9%

Premarket:1.89+0.62 (+49.2%)

Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

Business WireMon, 20-Dec 7:00 AM

CANF Can Fite Biofarma2.04+0.06+3.0%

Premarket:3.54+1.50 (+73.5%)

Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

Business WireTue, 16-Mar 7:00 AM

CANF Can Fite Biofarma2.35-0.03-1.3%

Premarket:3.22+0.87 (+37.0%)

New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson

Business WireMon, 22-Feb 7:10 AM

CANF Can Fite Biofarma1.84-0.04-2.1%

Premarket:2.39+0.55 (+29.9%)

Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Business WireWed, 15-Jul 7:00 AM

CANF Can-Fite Biopharma ADR1.45-0.03-2.0%

Premarket:2.56+1.11 (+76.6%)

Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

Business WireMon, 13-Apr 6:30 AM